Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

NCT01019694 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

470

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Combivent CFC-MDI
DRUG: Combivent Respimat 20/100 mcg
DRUG: Atrovent HFA 42 mcg + Albuterol HFA 200 mcg

Sponsor

Boehringer Ingelheim